Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator

Kelsey L. Briggs

doi:10.1016/j.drudis.2026.104688

Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator

2026-04-30

0

PRE

AI

K

Kelsey L. Briggs

B

Betsy J. Russell

P

Peter Warner

K

Ken Duncan

S

Steven J. Berthel *

DOI：10.1016/j.drudis.2026.104688

Original

Original request for help

Save

Abstract

En 中文

• Decentralized Tuberculosis Drug Accelerator model delivers disciplined, outcome-driven tuberculosis drug discovery. • Goal-driven, evolving membership aligns with shifting tuberculosis drug discovery needs. • Legal and data-sharing frameworks make early transparency a prerequisite for consortium support. • Two-tier pre-portfolio and portfolio system balances exploration with focused investment. • Semiannual meetings and working groups sustain learning and adaptive strategy.

Keywords:

Drug discovery

Tuberculosis

Consortium management

Adaptive strategy

Data-sharing frameworks

Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator

Abstract

Journal

Organization

Cited Papers

Citing Papers